MetLife Investment Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

MetLife Investment Management’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$224K	Sell	63,767 -23,754	-27%	-$97.4K	﹤0.01%	2174
2025 Q4	$295K	Buy	87,521 +29,512	+51%	+$76.6K	﹤0.01%	2079
2025 Q3	$76K	Buy	+58,009	New	+$60K	﹤0.01%	2744
2025 Q2	–	Sell	-67,229	Closed	-$98.8K	–	2880
2025 Q1	$98.8K	Sell	67,229 -22,026	-25%	-$52.5K	﹤0.01%	2531
2024 Q4	$395K	Buy	89,255 +8,559	+11%	+$34.7K	﹤0.01%	1920
2024 Q3	$332K	Hold	80,696	–	–	﹤0.01%	2002
2024 Q2	$526K	Buy	80,696 +9,126	+13%	+$64.6K	﹤0.01%	1695
2024 Q1	$623K	Hold	71,570	–	–	﹤0.01%	1560
2023 Q4	$819K	Hold	71,570	–	–	0.01%	1415
2023 Q3	$689K	Hold	71,570	–	–	0.01%	1441
2023 Q2	$762K	Buy	71,570 +1,442	+2%	+$15.5K	0.01%	1426
2023 Q1	$738K	Hold	70,128	–	–	0.01%	1401
2022 Q4	$869K	Hold	70,128	–	–	0.01%	1284
2022 Q3	$727K	Sell	70,128 -6,005	-8%	-$68.1K	0.01%	1376
2022 Q2	$878K	Sell	76,133 -3,116	-4%	-$36.7K	0.01%	1278
2022 Q1	$997K	Buy	79,249 +28,288	+56%	+$324K	0.01%	1327
2021 Q4	$594K	Hold	50,961	–	–	﹤0.01%	1418
2021 Q3	$666K	Sell	50,961 -10,033	-16%	-$130K	0.01%	1365
2021 Q2	$785K	Hold	60,994	–	–	0.01%	1304
2021 Q1	$682K	Buy	60,994 +296	+0.5%	+$3.13K	0.01%	1349
2020 Q4	$691K	Sell	60,698 -9,265	-13%	-$101K	0.01%	1311
2020 Q3	$629K	Hold	69,963	–	–	0.01%	1250
2020 Q2	$722K	Hold	69,963	–	–	0.01%	1182
2020 Q1	$706K	Hold	69,963	–	–	0.01%	1050
2019 Q4	$931K	Hold	69,963	–	–	0.01%	1132
2019 Q3	$601K	Hold	69,963	–	–	0.01%	1319
2019 Q2	$765K	Sell	69,963 -6,073	-8%	-$68K	0.01%	1240
2019 Q1	$862K	Hold	76,036	–	–	0.01%	1142
2018 Q4	$660K	Hold	76,036	–	–	0.01%	1202
2018 Q3	$1.18M	Hold	76,036	–	–	0.01%	1059
2018 Q2	$1.22M	Hold	76,036	–	–	0.01%	949
2018 Q1	$983K	Hold	76,036	–	–	0.01%	1015
2017 Q4	$955K	Buy	+76,036	New	+$993K	0.01%	1051

Other funds holding IRWD

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MetLife Investment Management's IRWD Position: Q1 2026 in Review

MetLife Investment Management reduced its Ironwood Pharmaceuticals (IRWD) stake by 27% in Q1 2026, selling an estimated $97.4K and leaving 63,767 shares worth $224K. The position accounts for ﹤0.01% of the portfolio, ranked #2174.

MetLife Investment Management first reported a position in IRWD in Q4 2017 and has held it in 33 quarters since. The position peaked at $1.22M in Q2 2018. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

MetLife Investment Management held 63,767 shares of Ironwood Pharmaceuticals worth $224K as of Q1 2026.
MetLife Investment Management sold 23,754 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $97.4K.
Ironwood Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2174 holding.
MetLife Investment Management first reported a position in Ironwood Pharmaceuticals in Q4 2017 and has held it in 33 quarters since.
MetLife Investment Management's Ironwood Pharmaceuticals position peaked at $1.22M in Q2 2018.
226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.